HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hitoshi Asamoto Selected Research

MVP protocol 2

10/2003[Lung toxicity of trimodality chemoradiotherapy with mitomycin C, vindesine, and cisplatin followed by surgery for locally advanced non-small cell lung cancer].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hitoshi Asamoto Research Topics

Disease

3Asthma (Bronchial Asthma)
11/2012 - 05/2010
1Chylothorax
10/2003
1Empyema
10/2003
1Large Cell Carcinoma
10/2003
1Adenocarcinoma
10/2003
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2003
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2003

Drug/Important Bio-Agent (IBA)

1Oxygen (Dioxygen)IBA
05/2010
1Cisplatin (Platino)FDA LinkGeneric
10/2003
1Vindesine (Vindesin)IBA
10/2003
1Mitomycin (Mitomycin-C)FDA LinkGeneric
10/2003

Therapy/Procedure

2Drug Therapy (Chemotherapy)
11/2012 - 10/2003
1Long-Term Care
11/2010
1Radiotherapy
10/2003
1Sutures (Suture)
10/2003
1MVP protocol 2
10/2003
1Chemoradiotherapy
10/2003